Related Experiment Video

Updated: Jan 20, 2026

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.1K

Does Ivabradine Decrease Cardiovascular Deaths in Heart Failure Patients?

Thomas A Marciniak1, Dan Atar2, Victor Serebruany3

  • 139344 Hatteras Drive, Bethany Beach, Del.

The American Journal of Medicine
|August 24, 2019
PubMed

Insights

Ivabradine, a heart rate-lowering medication, shows improved cardiovascular death outcomes when used with loop diuretics. This combination therapy offers a potential benefit for patients with heart conditions.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Ivabradine is a heart rate-slowing drug for heart failure and angina.
  • Its cardiovascular event impact varied across three major trials.
  • FDA analyses investigated these outcome variations.

Purpose of the Study:

  • To analyze the variability in cardiovascular event outcomes for ivabradine across trials.
  • To investigate potential interactions between ivabradine and concomitant medications.

Main Methods:

  • Utilized logistic regressions to assess drug interactions.
  • Employed forest plots to visualize dose-response relationships.
  • Analyzed raw data from three large ivabradine outcome trials (SHIFT, BEAUTIFUL, SIGNIFY).

Main Results:

  • A significant beneficial interaction was observed between ivabradine and loop diuretics in the SHIFT heart failure trial, reducing cardiovascular deaths (OR 0.61).
  • This favorable interaction was consistent across the BEAUTIFUL and SIGNIFY trials.
  • A dose-response relationship between loop diuretics and ivabradine was evident in the SHIFT and BEAUTIFUL trials, independent of heart failure severity.

Conclusions:

  • Concomitant use of ivabradine with loop diuretics demonstrates a beneficial impact on cardiovascular mortality.
  • This finding suggests a synergistic effect that warrants further clinical consideration.
Abstract

Keywords:
Cardiovascular mortalityDrug interactionHeart failureIvabradineLoop diuretics

More Related Videos

Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure04:20

Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure

Published on: October 1, 2019

6.2K
Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis04:05

Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis

Published on: June 30, 2023

2.8K

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
768
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.0K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
720
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
273
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
821
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
225